Search
Back 

2018 Announcements

2018 Announcements

February 19, 2018

NRG Oncology NCORP Pilot Projects
NRG Oncology NCORP is soliciting PILOT projects for applications focused on NRG NCORP Cancer Prevention and Control (CPC) priorities
that will provide data that will directly lead to future Phase II-III CPC concepts. As put forward in our core grant, CPC priorities for funding are:

  •  Cancer prevention research aimed at identifying and evaluating interventions to reduce the risk and incidence of cancer 
  •  Cancer control research aimed at reducing the incidence and co-morbidity of cancer and its treatment focused on the four symptomatic management  themes: neurotoxicity, cardiotoxicity, lymphedema, and inflammation (including cancer-related fatigue)
  •  Survivorship and palliative care interventions aimed at reducing toxicity and symptom burden, and improving quality of life (QoL)
  •  Cancer disparity research, in collaboration with our Health Disparities Research (HDR) Program, focused on efforts to increase the participation of  minorities and underserved populations in CPC studies
  •  Integral to these priorities, are the establishment of biospecimen repositories for molecular studies. 

​For full details read more

NRG Oncology NCORP is soliciting PILOT projects for applications focused on NRG NCORP Cancer Care Delivery Research priorities that will provide data that will directly lead to future CCDR concepts.  As put forward in our core grant, CCDR priorities for funding are:

  • Implementation of guideline-based care
  • Patient-reported outcomes (PROs) 
  • Decision-making tools 
  • Patient navigation 
  • Cardiotoxicity 
  • Survivorship and surveillance

For full details read more


February 14, 2018

NRG Oncology Appoints NCORP Investigator, Matthew Hudson, as Cancer Care Delivery Research  Committee Co-Chair

HudsonWeb

NRG Oncology recently appointed Matthew F. Hudson, PhD, MPH as Co-Chair for the organization’s Cancer Care Delivery Research (CCDR) Committee. He joins the present Co-Chair Debra Ritzwoller in the leadership of this committee. Drs. Hudson and Ritzwoller each represent a National Cancer Institute (NCI) Community Oncology Research Program (NCORP) institution. Participating NCORP community sites, like the ones Drs. Hudson and Ritzwoller represent, make cancer research available to larger and more diverse patient populations. Dr. Hudson’s addition to the leadership team may enhance NRG Oncology’s capacity to evolve community-informed research protocols. Read more



February 13, 2018

Aghajanian Appointed as NRG Oncology Gynecologic Cancer Committee Chair

Aghajanian_2017_opt636541261220150055


Carol Aghajanian, MD of Memorial Sloan Kettering Cancer Center (MSK) in New York has been named Chair of NRG Oncology’s Gynecologic Cancer Committee. Dr. Aghajanian’s experience in gynecologic cancer research and her leadership at MSK and within the National Cancer Institute (NCI)’s National Clinical Trials Network (NCTN) will be invaluable to NRG Oncology as the organization pursues its mission of improving the lives of cancer patients through multi-institutional clinical and translational research. She follows the prior NRG Oncology Gynecologic Cancer Committee Chair, Robert S. Mannel, MD, who was elected as an NRG Oncology Group Chair in 2017. Read more



February 1, 2018

NRG Oncology Appoints Kati Stoermer for New Executive Director Role 

Stoermer636530970992044892

NRG Oncology, one of the five funded network groups within the National Cancer Institute (NCI)’s National Clinical Trials Network (NCTN), has appointed Kati Stoermer as the organization’s Executive Director. In this new role, Stoermer will be providing oversight and management of the NRG Oncology operational activities coordinated by staff located in Philadelphia and Pittsburgh. She will also be coordinating with the organization’s Statistical and Data Management Center and the group’s Biospecimen Bank. Read more

 

 

NRG Oncology, one of the five funded network groups within the National Cancer Institute (NCI)’s National Clinical Trials Network (NCTN), has appointed Kati Stoermer as the organization’s Executive Director. In this new role, Stoermer will be providing oversight and management of the NRG Oncology operational activities coordinated by staff located in Philadelphia and Pittsburgh. She will also be coordinating with the organization’s Statistical and Data Management Center and the group’s Biospecimen Bank. Read more. 
NRG Oncology, one of the five funded network groups within the National Cancer Institute (NCI)’s National Clinical Trials Network (NCTN), has appointed Kati Stoermer as the organization’s Executive Director. In this new role, Stoermer will be providing oversight and management of the NRG Oncology operational activities coordinated by staff located in Philadelphia and Pittsburgh. She will also be coordinating with the organization’s Statistical and Data Management Center and the group’s Biospecimen Bank. Read more. 
NRG Oncology, one of the five funded network groups within the National Cancer Institute (NCI)’s National Clinical Trials Network (NCTN), has appointed Kati Stoermer as the organization’s Executive Director. In this new role, Stoermer will be providing oversight and management of the NRG Oncology operational activities coordinated by staff located in Philadelphia and Pittsburgh. She will also be coordinating with the organization’s Statistical and Data Management Center and the group’s Biospecimen Bank. Read more. 

Copyright 2018 by NRG Oncology